Milestone (MIST) Receives Buy Rating After China Approval

H.C. Wainwright has reiterated a Buy rating for Milestone Pharmaceuticals (MIST) following the company's approval to market its product in China. This approval represents a significant milestone for the company as it expands into the Chinese market, potentially increasing its revenue prospects. The positive outlook from the analyst suggests confidence in Milestone's future performance. This matters for investors as a successful entry into the China market could boost Milestone's stock performance significantly.